Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: An ideal treatment option in terms of the adverse effect

Hiroyuki Uchida, Takefumi Suzuki, Ryoko Yamazawa, Masayuki Tomita, Takahiro Nemoto, Yoshie Kimura, Koichiro Watanabe, Yasushi Imasaka, Haruo Kashima

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

There are sporadic reports of antipsychotic-induced visual hypersensitivity attack (VHA). VHA is characterized by hypersensitivity of perception mainly in the visual modality and sometimes accompanied by an oculogyric crisis. However, some researchers regard VHA as a schizophrenia symptom. To determine whether VHA is an adverse effect of antipsychotic agents, we examined the effect of dose reduction on VHA. This was an open-label 36-week study. We randomized 34 patients with VHA to a reduced-dose group and a fixed-dose group. Primary outcome measures were the frequency and duration of VHA, assessed with patients' self-reports, and the Clinical Global Impressions (CGI). Assessment also included the Drug-induced Extrapyramidal Symptoms Scale for extrapyramidal symptoms, the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, and the CGI for other diagnoses. Data were collected from August 2000 to April 2005 at 4 psychiatric hospitals in Tokyo. VHA diminished in 16 patients (94.1%) in the reduced-dose group in the CGI score, the frequency (number of episodes per week), and the duration of the episodes (from 4.06 to 1.77, P < 0.001; from 2.59 to 0.82, P = 0.001; and from 1.92 to 0.66 hours, P = 0.007, respectively), but there were no changes in the fixed-dose group. There were no changes in the underlying illness as measured by the PANSS in both groups. Reducing the dose of antipsychotic agents ameliorates VHA and represents the ideal treatment option for patients with VHA.

Original languageEnglish
Pages (from-to)50-55
Number of pages6
JournalJournal of Clinical Psychopharmacology
Volume26
Issue number1
DOIs
Publication statusPublished - 2006 Feb

Fingerprint

Antipsychotic Agents
Hypersensitivity
Therapeutics
Schizophrenia
Tokyo
Psychiatric Hospitals
Self Report
Research Personnel
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack : An ideal treatment option in terms of the adverse effect. / Uchida, Hiroyuki; Suzuki, Takefumi; Yamazawa, Ryoko; Tomita, Masayuki; Nemoto, Takahiro; Kimura, Yoshie; Watanabe, Koichiro; Imasaka, Yasushi; Kashima, Haruo.

In: Journal of Clinical Psychopharmacology, Vol. 26, No. 1, 02.2006, p. 50-55.

Research output: Contribution to journalArticle

Uchida, Hiroyuki ; Suzuki, Takefumi ; Yamazawa, Ryoko ; Tomita, Masayuki ; Nemoto, Takahiro ; Kimura, Yoshie ; Watanabe, Koichiro ; Imasaka, Yasushi ; Kashima, Haruo. / Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack : An ideal treatment option in terms of the adverse effect. In: Journal of Clinical Psychopharmacology. 2006 ; Vol. 26, No. 1. pp. 50-55.
@article{04a7284bac134d81991584c37be1b974,
title = "Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: An ideal treatment option in terms of the adverse effect",
abstract = "There are sporadic reports of antipsychotic-induced visual hypersensitivity attack (VHA). VHA is characterized by hypersensitivity of perception mainly in the visual modality and sometimes accompanied by an oculogyric crisis. However, some researchers regard VHA as a schizophrenia symptom. To determine whether VHA is an adverse effect of antipsychotic agents, we examined the effect of dose reduction on VHA. This was an open-label 36-week study. We randomized 34 patients with VHA to a reduced-dose group and a fixed-dose group. Primary outcome measures were the frequency and duration of VHA, assessed with patients' self-reports, and the Clinical Global Impressions (CGI). Assessment also included the Drug-induced Extrapyramidal Symptoms Scale for extrapyramidal symptoms, the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, and the CGI for other diagnoses. Data were collected from August 2000 to April 2005 at 4 psychiatric hospitals in Tokyo. VHA diminished in 16 patients (94.1{\%}) in the reduced-dose group in the CGI score, the frequency (number of episodes per week), and the duration of the episodes (from 4.06 to 1.77, P < 0.001; from 2.59 to 0.82, P = 0.001; and from 1.92 to 0.66 hours, P = 0.007, respectively), but there were no changes in the fixed-dose group. There were no changes in the underlying illness as measured by the PANSS in both groups. Reducing the dose of antipsychotic agents ameliorates VHA and represents the ideal treatment option for patients with VHA.",
author = "Hiroyuki Uchida and Takefumi Suzuki and Ryoko Yamazawa and Masayuki Tomita and Takahiro Nemoto and Yoshie Kimura and Koichiro Watanabe and Yasushi Imasaka and Haruo Kashima",
year = "2006",
month = "2",
doi = "10.1097/01.jcp.0000195384.04008.25",
language = "English",
volume = "26",
pages = "50--55",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack

T2 - An ideal treatment option in terms of the adverse effect

AU - Uchida, Hiroyuki

AU - Suzuki, Takefumi

AU - Yamazawa, Ryoko

AU - Tomita, Masayuki

AU - Nemoto, Takahiro

AU - Kimura, Yoshie

AU - Watanabe, Koichiro

AU - Imasaka, Yasushi

AU - Kashima, Haruo

PY - 2006/2

Y1 - 2006/2

N2 - There are sporadic reports of antipsychotic-induced visual hypersensitivity attack (VHA). VHA is characterized by hypersensitivity of perception mainly in the visual modality and sometimes accompanied by an oculogyric crisis. However, some researchers regard VHA as a schizophrenia symptom. To determine whether VHA is an adverse effect of antipsychotic agents, we examined the effect of dose reduction on VHA. This was an open-label 36-week study. We randomized 34 patients with VHA to a reduced-dose group and a fixed-dose group. Primary outcome measures were the frequency and duration of VHA, assessed with patients' self-reports, and the Clinical Global Impressions (CGI). Assessment also included the Drug-induced Extrapyramidal Symptoms Scale for extrapyramidal symptoms, the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, and the CGI for other diagnoses. Data were collected from August 2000 to April 2005 at 4 psychiatric hospitals in Tokyo. VHA diminished in 16 patients (94.1%) in the reduced-dose group in the CGI score, the frequency (number of episodes per week), and the duration of the episodes (from 4.06 to 1.77, P < 0.001; from 2.59 to 0.82, P = 0.001; and from 1.92 to 0.66 hours, P = 0.007, respectively), but there were no changes in the fixed-dose group. There were no changes in the underlying illness as measured by the PANSS in both groups. Reducing the dose of antipsychotic agents ameliorates VHA and represents the ideal treatment option for patients with VHA.

AB - There are sporadic reports of antipsychotic-induced visual hypersensitivity attack (VHA). VHA is characterized by hypersensitivity of perception mainly in the visual modality and sometimes accompanied by an oculogyric crisis. However, some researchers regard VHA as a schizophrenia symptom. To determine whether VHA is an adverse effect of antipsychotic agents, we examined the effect of dose reduction on VHA. This was an open-label 36-week study. We randomized 34 patients with VHA to a reduced-dose group and a fixed-dose group. Primary outcome measures were the frequency and duration of VHA, assessed with patients' self-reports, and the Clinical Global Impressions (CGI). Assessment also included the Drug-induced Extrapyramidal Symptoms Scale for extrapyramidal symptoms, the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, and the CGI for other diagnoses. Data were collected from August 2000 to April 2005 at 4 psychiatric hospitals in Tokyo. VHA diminished in 16 patients (94.1%) in the reduced-dose group in the CGI score, the frequency (number of episodes per week), and the duration of the episodes (from 4.06 to 1.77, P < 0.001; from 2.59 to 0.82, P = 0.001; and from 1.92 to 0.66 hours, P = 0.007, respectively), but there were no changes in the fixed-dose group. There were no changes in the underlying illness as measured by the PANSS in both groups. Reducing the dose of antipsychotic agents ameliorates VHA and represents the ideal treatment option for patients with VHA.

UR - http://www.scopus.com/inward/record.url?scp=31544463789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544463789&partnerID=8YFLogxK

U2 - 10.1097/01.jcp.0000195384.04008.25

DO - 10.1097/01.jcp.0000195384.04008.25

M3 - Article

C2 - 16415706

AN - SCOPUS:31544463789

VL - 26

SP - 50

EP - 55

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -